BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6492 related articles for article (PubMed ID: 29269008)

  • 1. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 3. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
    Zhang L; Chen Y; Wang H; Xu Z; Wang Y; Li S; Liu J; Chen Y; Luo H; Wu L; Yang Y; Zhang H; Peng H
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 5. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
    Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
    Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 325.